Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy
In conclusion, HER2-ultralow status is not associated with distinct clinicopathologic or genomic characteristics. HER2-IHC 0 (MS-) and ultralow statuses often coexist within the same patient.
Authors
- Hong Lv (ORCID: https://orcid.org/0000-0002-2129-2781)
- Biyun Wang (ORCID: https://orcid.org/0000-0002-7829-1544)
- Zhonghua Tao (ORCID: https://orcid.org/0000-0003-3975-3803)
- Leiping Wang (ORCID: https://orcid.org/0000-0002-0605-1621)
- Juan Jin (ORCID: https://orcid.org/0000-0003-2513-4665)
- Xichun Hu (ORCID: https://orcid.org/0000-0001-6148-9186)
- Mengyuan Cai (ORCID: https://orcid.org/0000-0002-1152-5895)
- Hongxia Wang (ORCID: https://orcid.org/0000-0003-3481-6940)
- Tiantian Liu (ORCID: https://orcid.org/0000-0001-5384-0642)
- Wentao Yang (ORCID: https://orcid.org/0000-0002-6108-7301)
- Mingchuan Zhao
- Duanchen Guo
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Precision Clinical Medicine
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1093/pcmedi/pbaf026
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05